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S U M M A R Y
Objectives: This study was designed to establish an ELISA method, as well as the cut-off value, for IgA
against Epstein–Barr virus (EBV) viral capsid antigen (VCA), as a screening assay for nasopharyngeal
carcinoma (NPC) in southern China. In addition, the correlation between relative optical density (rOD)
values from ELISA and titers from the immunoenzymatic assay (IEA) was also evaluated.
Methods: Two hundred and ﬁfty-eight NPC cases, 33 non-NPC head and neck cancer patients, and 1156
healthy controls were recruited for this study. VCA-IgA and early antigen (EA)-IgA were measured by
ELISA kits and IEA in parallel.
Results: The total precision of the VCA-IgA ELISA achieved a level of <13.0% coefﬁcient of variation. An
rOD value of 1.60 for the VCA-IgA ELISA was determined as the cut-off point for southern China, and the
sensitivity and speciﬁcity for NPC diagnosis when using this cut-off value were 93.0% and 92.4%,
respectively. The area under the receiver operating characteristic curve (ROC-AUC) value was 0.969. The
correlation coefﬁcient between titers and rOD values was 0.957. rOD values were correlated with NPC
overall stage and lymph node involvement.
Conclusions: The cut-off level established in our study could be used to facilitate more accurate diagnosis
of NPC in southern China. The rOD value might be an index for NPC prognosis, since it shows a good
correlation with the titer from IEA.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Nasopharyngeal carcinoma (NPC) is a squamous cell cancer that
develops in the epithelium of the nasopharynx. It has a high
incidence among individuals from certain regions, such as
southern China.1,2
The prognosis of NPC is affected by multiple factors, such as the
NPC stage, local invasion, performance status, and histological
subtype.3,4 Besides dietary and genetic factors, Epstein–Barr virus
(EBV) infection has also been proven to play an important role in
the causation of non-keratinizing NPC. EBV DNA is detectable in
most non-keratinizing NPC patients. More importantly, EBV DNA* Corresponding author.
E-mail address: liuwl@sysucc.org.cn (WL. Liu).
1 These authors contributed equally.
http://dx.doi.org/10.1016/j.ijid.2014.03.1373
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).appears to correlate with the treatment response and disease
recurrence. Findings from population-based studies also suggest
that IgA antibodies against EBV capsid antigen (VCA-IgA) might be a
biomarker for predicting the risk of NPC development.5,6. Serological
studies of EBV at the outset and at follow-up have been applied
widely to assist in staging and detecting recurrence.7–9
Anti-VCA IgA antibodies have been found to be sensitive
markers for NPC diagnosis and differential diagnosis.7,10 These
antibodies are traditionally measured via immunoﬂuorescence (IF)
or immunoenzymatic assay (IEA) using EBV-transformed lympho-
blastoid cell lines as targets. VCA-IgA and anti-early antigen IgA
(EA-IgA) antibodies are still serologically investigated by IEA in
most laboratories in southern China.11,12 However, the traditional
IEA method for EBV serological studies has some disadvan-
tages.10,13 This method is semi-quantitative and difﬁcult to
standardize.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(e.g. ELISA) speciﬁc for individual EBV-speciﬁed peptides could
avoid the inherent assay errors related to the inevitable
subjectivity of traditional methods, without a loss in sensitivity
and speciﬁcity.14–19
A close relationship between the titer of VCA-IgA and the long-
term outcome and cure of NPC has been reported.7–9 Thus, the titer
detected by traditional IEA and IFA has considerable prognostic
value, with which clinicians are very familiar.
Most commercial ELISA kits only produce either negative or
positive results. And few investigations have focused on the
relationship between the quantitative ELISA results of VCA-IgA
antibody and the prognosis of NPC.
As VCA-IgA has been proven to have signiﬁcant importance for
NPC early screening, it is necessary to establish a diagnostic cut-off
value for VCA-IgA with the ELISA method, especially in high NPC
incidence areas. Nevertheless, previous studies have mostly
concentrated on the IEA method instead of ELISA.7–9 There is an
urgent need for reference ranges or a cut-off value for routine VCA-
IgA detection by ELISA.
We designed this study to evaluate the performance of a
commercial VCA-IgA ELISA kit for NPC diagnosis in a high NPC
incidence area and offer further useful information for NPC
diagnosis. The relationship between the EBV VCA-IgA antibody
titer and the relative optical density (rOD) value was also studied.
2. Materials and methods
2.1. Study population
The NPC group comprised 258 newly diagnosed patients prior to
any treatment at enrollment. Two control groups – a group of 1156
healthy subjects and a disease control group of 33 patients with
head and neck tumors other than NPC – were also included. The
healthy subjects were all native residents of the Pearl River estuary
area in southern China, where a high incidence of NPC has been
observed and recognized worldwide. Healthy subjects underwent
preventive screening against NPC every year. Diagnosed NPC
patients had been histologically conﬁrmed by biopsy and further
tests, including head and neck magnetic resonance imaging (MRI)
and chest X-rays. The stages of disease progression were classiﬁed
according to the 2009 Union for International Cancer Control (UICC)
classiﬁcation. The NPC group included seven patients with stage I
NPC, 36 with stage II NPC, 126 with stage III NPC, and 89 with stage
IV NPC. One hundred and eighty-nine males and 69 females were
recruited, aged from 20 to 77 years, with a median age of 47 years.
2.2. Immunoenzymatic assay (IEA)
Serological tests for VCA-IgA and EA-IgA antibodies were
performed with an IEA supplied by the Shanghai Institute of
Biological Products. IEAs were prepared from the B95 cell line for
VCA, and the Raji cell line for EA. Plasma samples were screened at
a dilution of 1:10, followed by two-fold serial dilutions. The
antibody titer was the reciprocal of the highest dilution clearly
showing a brown color within 15% of the cells. Levels of VCA-IgA
and EA-IgA were determined by titration, with the cut-off values
set at 1:40 for VCA-IgA and 1:10 for EA-IgA.
2.3. ELISA for EBV VCA-IgA and EA-IgA
Antibodies directed at VCA-IgA and EA-IgA were determined by
ELISA using commercial kits manufactured by EUROIMMUN,
Germany. The experiments were conducted in accordance with
the manufacturer’s test instructions. A calibrator for calculation
and a negative control and positive control for internal qualityassessment were included on each plate. Final results were
evaluated semi-quantitatively by calculating the ratio of the OD
value of the sample over the OD value of the calibrator, expressed
as relative OD (rOD).
2.4. Linearity range
Tests for validating the linearity range of the VCA-IgA ELISA were
performed based on guidelines from the Clinical and Laboratory
Standards Institute (CLSI). Since there are no international standards
for EBV antibodies, the linearity of the ELISA test was investigated by
assaying serial dilutions of patient samples with high antibody
concentrations. Ten patient samples with a titer of 1:1280 on IEA
were mixed together and tested by double dilution. The dilution
points were in order, 1:640, 1:320, 1:160, 1:80, 1:40, 1:20, and 1:10.
Each dilution point was tested in duplicate.
2.5. Precision performance
Precision performance of the VCA-IgA ELISA was assessed
according to the guidelines of CLSI document EP05-A2. Tests were
performed with a single lot of the kit. Five samples with different
titers (1:20, 1:40, 1:80, 1:160, and 1:640) in IEA results were
selected. Each titer was determined using a mixture of 10 blood
samples. The ﬁve samples and quality controls (QC) were assayed
twice per day over a 20-day period.
2.6. Correlation between IEA titer and ELISA rOD value of VCA-IgA
antibody
Samples from 166 healthy subjects with a positive titer on IEA
and 258 patients diagnosed with NPC were analyzed to determine
the correlation between the two methods. IEA titer values were
converted into log2(1/titer).
2.7. Statistical analysis
A receiver operating characteristic (ROC) curve was constructed
by plotting sensitivity versus 1  speciﬁcity, and the area under the
curve (AUC) was analyzed with the Hanley and McNeil method.
The cut-off value was identiﬁed when the highest sensitivity and
speciﬁcity were chosen from the respective ROC. All statistical
tests were two-sided and a p-value <0.05 was considered
statistically signiﬁcant. All statistical analyses were performed
using IBM SPSS Statistics for Windows, version 19.0 (IBM Corp.,
Armonk, NY, USA).
3. Results
3.1. Linearity range of the VCA-IgA ELISA
The linear range of the VCA-IgA ELISA kit was not demonstrated
by the manufacturer. Furthermore, there were no international
reference standards for EBV VCA-IgA antibody. High-concentration
samples from NPC patients were taken as an internal positive
control of high value. Mixed serum samples with an IEA titer of
1:1280 were diluted to 1:640, 1:320, 1:160, 1:80, 1:40, 1:20, and
1:10. These diluted samples were also determined by ELISA with
rOD values. Samples with a titer of 1:1280 exceeded the linear
range of the ELISA kit in our experiment. A point to point plot was
drawn using titers and corresponding rOD values for all samples
except those with a titer of 1:1280. When measured values were
compared to expected values, the linearity was found to ﬁt the
following equation: y = 1.09x  6.33, r = 0.91 (x: rOD value, y:
converted titer). A good linear range from 1:10 to 1:640 was
demonstrated.
Table 1
Precision data for the VCA-IgA ELISA over a 20-day evaluation period
Precision (CV %)
Titer
of IEA
rOD
(mean  SD)
Repeatability Between-run Between-day Total
1:20 1.43  0.12 1.92 0.65 12.9 18.76
1:40 3.09  0.10 3.18 1.63 5.53 6.59
1:80 5.88  0.68 5.84 2.76 11.51 12.53
1:160 8.31  0.41 2.31 1.39 4.56 5.30
1:640 14.90  1.53 3.84 5.15 4.78 8.00
VCA, viral capsid antigen; CV, coefﬁcient of variation; IEA, immunoenzymatic assay;
rOD, relative optical density; SD, standard deviation.
Figure 1. Distribution of VCA-IgA rOD values in the different age groups (VCA, viral
capsid antigen; rOD, relative optical density.).
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The titers of samples tested for precision evaluation ranged
from 1:20 to 1:640. The reproducibility of the ELISA test was
investigated by determining the inter-assay coefﬁcients of
variation (CV) using ﬁve samples. The VCA-IgA ELISA showed a
total precision performance of less than 13.0% CV for all assessed
panels except the one with the titer of 1:20, for which total
precision was 18.76% CV. Repeatability, between-run, and
between-day precision were also investigated and are summarized
in Table 1.
3.3. Characteristics of the study groups
Distributions of age, gender, and VCA-IgA rOD values for each
study group are shown in Table 2. Mean rOD values for males and
females in the different age groups showed no marked differences
(p > 0.05), except in one age group (20–29 years) (p = 0.02). Mean
rOD values were not signiﬁcantly different between the six age
groups by one-way analysis of variance (ANOVA) test (p > 0.05)
(Figure 1).
The median VCA-IgA rOD value for healthy individuals was
0.74 (95% conﬁdence interval (CI) 0.68–0.80). The values for
patients with non-NPC head and neck cancer and NPC were 0.72
(95% CI 0.39–1.05) and 7.50 (95% CI 6.93–8.07), respectively. The
distribution of the assayed values for the different study groups is
illustrated in Figure 2. There was no signiﬁcant difference
between patients with non-NPC head and neck cancer andTable 2
Results of VCA-IgA ELISA rOD by age group
Age,
years
Sex n rOD
(mean)
95% CI p-Valuea Upper
reference
limitb
20–29 Male 73 0.59 (0.40–0.79) 0.02 1.52
Female 174 0.43 (0.29–0.58) 1.12
30–39 Male 100 0.52 (0.39–0.65) 0.58 1.14
Female 210 0.75 (0.43–1.05) 2.21
40–49 Male 117 0.80 (0.25–1.36) 0.09 3.39
Female 166 0.48 (0.29–0.68) 1.40
50–59 Male 43 0.67 (0.43–0.90) 0.44 1.77
Female 102 0.70 (0.46–0.94) 1.82
60–69 Male 44 0.72 (0.49–0.95) 0.07 1.80
Female 51 0.69 (0.51–0.88) 1.58
70 Male 37 0.85 (0.47–1.24) 0.26 2.65
Female 39 0.84 (0.51–1.16) 2.37
35–55c Male 234 0.77 (0.65–0.90) 0.92 2.31
Female 342 0.58 (0.49–0.67) 1.76
All Male 414 0.59 (0.40–0.79) 0.68 1.52
Female 742 0.42 (0.32–0.52) 0.90
All 1156 0.74 (0.68–0.80) 2.45
VCA, viral capsid antigen; rOD, relative optical density; CI, conﬁdence interval.
a p-Values were calculated by comparison for each age group by male and female.
b One-sided 95% upper limit.
c The 35–55 years age group was analyzed separately, because this age range is
recognized to have a high incidence of nasopharyngeal carcinoma.healthy subjects (p = 0.947). However, a statistically signiﬁcant
difference was found between the NPC and healthy subjects
groups (p < 0.001).
3.4. Cut-off value for rOD and diagnostic performances of VCA-IgA
ELISA and IEA
Even though the manufacturer recommended its own cut-off
point in the test instructions, we decided to establish an in-houseFigure 2. The rOD values of VCA-IgA from ELISA presented a signiﬁcant difference
between the NPC group and the HS group (p < 0.001), while no signiﬁcant difference
was found between the non-NPC head and neck cancer group and the HS group (p =
0.947) (rOD, relative optical density; VCA, viral capsid antigen; NPC,
nasopharyngeal carcinoma; HS, healthy subjects.).
Figure 3. ROC curves of VCA-IgA ELISA for discriminating NPC (n = 258) from non-
NPC head and neck cancer (n = 33) and HS (n = 1156). The ROC-AUC value was 0.969
(95% CI 0.957–0.981; p < 0.001) (ROC, receiver operating characteristic; VCA, viral
capsid antigen; NPC, nasopharyngeal carcinoma; HS, healthy subjects; AUC, area
under the curve.).
Table 3
Sensitivities and speciﬁcities of VCA-IgA and EA-IgA for detecting nasopharyngeal
carcinoma by ELISA and IEA
Cut-off level
ELISA (rOD) IEA titer
Parameter 0.80a 1.10a 1.60 2.45 1:20 1:40 1:80
Sensitivity (%) 98.4 96.5 93.0 86.3 96.4 91.6 85.1
Speciﬁcity (%) 74.4 81.4 92.4 96.0 90.3 96.0 98.3
Sensitivity (%)b 88.4 87.6 86.8 82.2 88.4 87.5 85.3
Speciﬁcity (%)b 98.8 99.2 99.6 99.6 99.2 99.2 99.2
Sensitivity (%)c 87.6 87.6 87.6 87.6 87.6 87.6 87.2
Speciﬁcity (%)c 88.0 91.5 96,9 98.4 96.9 99.2 99.2
VCA, viral capsid antigen; EA, early antigen; IEA, immunoenzymatic assay; rOD,
relative optical density.
a The cut-off levels of suspected positive and positive delimited by the
manufacturer.
b The sensitivity and speciﬁcity of EBV EA-IgA were assayed by IEA as a follow-up
test on EBV VCA-IgA-positive samples.
c The sensitivity and speciﬁcity of EBV EA-IgA were assayed by ELISA as a follow-
up test on EBV VCA-IgA-positive samples.
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diagnostic capability of the tests and to deﬁne an optimal cut-off
value (Figure 3).
The ROC-AUC value for discriminating NPC patients (n = 258)
from non-NPC head and neck cancer patients (n = 33) and healthy
individuals (n = 1156) was 0.969 (95% CI 0.957–0.981; p < 0.001).
The sensitivity and speciﬁcity of the ELISA and IEA tests are
summarized in Table 3. Taking the 95% upper reference limit as the
cut-off point, the sensitivity and speciﬁcity of the VCA-IgA ELISA
were 86.3% and 96.0%, respectively. The sensitivity decreases with
an increase in the cut-off point, while the speciﬁcity increases as
the cut-off point increases. When using 1.60 as the cut-off point,
the sensitivity and speciﬁcity of the VCA-IgA ELISA were 93.0% and
92.4%, respectively. As the EBV EA-IgA assay is recommended as a
follow-up supplementary test for NPC screening after positive
results by EBV VCA-IgA assay, the performance of the IEA and ELISA
tests for EBV EA-IgA were further analyzed using only a cohort of
EBV VCA-IgA-positive samples (Table 3). The sensitivity and
speciﬁcity of both methods were similar for each cut-off value
group, except the one with the cut-off of 2.45. The sensitivity and
speciﬁcity of the ELISA were close to those of the IEA when an rOD
of 1.6 was chosen as the cut-off point. We also found that the
detection combined with EBV EA-IgA improved the speciﬁcity, but
greatly reduced the detection sensitivity.
3.5. Relationship between IEA titer and rOD value of VCA-IgA ELISA
One hundred and sixty-six healthy subjects with positive titers
and 258 NPC patients were investigated to establish the correlationTable 4
Characteristics of the relationship between titer and mean rOD
1:20a 1:40 1:80 
HS, n 120 26 12 
NPC, n 15 18 35 
All, n 135 44 47 
Mean rOD 1.19 2.53 3.25 
(95% CI) (0.98–1.40) (1.85–3.2) (2.51–3.98
rOD, relative optical density; IEA, immunoenzymatic assay; HS, healthy subjects; NPC,
a Titers of 1:10 and 1:20 were placed into one group, as they are not easy to differe
b Titers of 1:640 and 1:1280 were placed into one group, since a titer of 1:1280 excof titers and rOD values (Table 4). VCA-IgA was analyzed by both
ELISA and IEA. The rOD values were compared to the titers, and
then the correlation between the two assays was established
(Figure 4). According to this study, we can assign the correspond-
ing titer to the rOD value for efﬁcacy and prognostic evaluation
(Table 4).
3.6. rOD values from VCA-IgA ELISA and clinical stage of NPC
The rOD values for patients at different clinical stages of NPC
were compared. In general, the median rOD value rises with the
NPC stage, given 5.56, 7.14, and 9.24 for stages I–II, III, and IV,
respectively (Figure 5); a signiﬁcant overall difference was found (p
< 0.001). The median rOD value in patients with stage IV NPC was
1.7-fold greater than the median level in patients with early stages
of NPC (stages I and II). When investigating the TNM classiﬁcations,
no signiﬁcant differences were found for rOD levels among T
classes or between M0 and M1 classes (Figure 5). However,
patients with and without tumor spread to the lymph nodes
showed different rOD levels in this study. The absence of tumor
cells from the regional lymph nodes signiﬁcantly lowered the rOD
values in NPC patients (Figure 5); however, the degree of spread to
the lymph nodes had no inﬂuence on rOD levels.
4. Discussion
In this study, we evaluated the analytical and diagnostic
performance of an EBV VCA-IgA ELISA kit by calculating the rOD
units.
ELISA results with a CV of less than 20% are generally considered
to be repeatable and clinically acceptable. This assay showed an
excellent performance with a CV of less than 15% in almost allIEA titer
1:160 1:320 1:640b
5 3 0
59 63 68
64 66 68
5.54 7.28 12.06
) (4.44–6.65) (6.10–8.46) (10.74–13.38)
 nasopharyngeal carcinoma; CI, conﬁdence interval.
ntiate under microscope by IEA.
eeded the linear range and its rOD value was similar to that for 1:640.
Figure 4. Relationship between titers and mean rOD; IEA titers were converted into
log2(1/titer) (rOD, relative optical density; IEA, immunoenzymatic assay.).
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knowledge, not yet been determined by the World Health
Organization (WHO) International Laboratory and Collaborating
Centres for Biological Standards. We attempted to evaluate the
linear range in an uncomplicated manner. Titers of 1:1280
exceeded the linear range and their OD values were similar to
those for 1:640 titers in this study. Hence, titers of 1:1280 were
allocated to the 1:640 titer group in the subsequent study.
We analyzed plasma VCA-IgA rOD values for 1156 healthy
controls in different age and gender groups. There were no
statistically signiﬁcant differences between subgroups except for
the age group 20–29 years (p = 0.002). This may be due to one case
in the female group yielding an rOD value of 4.8. Interestingly, this
patient’s rOD value continued to drop over 3 years. ELISA-based
assays have demonstrated their sensitivity and speciﬁcity in both
screening and monitoring when compared with IF- and IEA-based
assays.20,21 Moreover, ELISA-based assays offer many advantages.Figure 5. Correlation between rOD values of VCA-IgA from ELISA and clinical TNM catego
(N factor); (c) distant metastasis (M factor); (d) overall stage (rOD, relative optical denThey are easier to standardize, with greater false tolerance to
interference, and are also more labor-saving when analyzing a
large number of specimens. However, the existing cut-off level for
the EBV VCA-IgA ELISA provided by the manufacturer was rough
and not suitable for high NPC incidence areas. Our study aimed to
improve this.
The ROC was evaluated by means of a plot of the true-positive
fraction (sensitivity) versus the true-negative fraction (1 
speciﬁcity) using a continuously varying decision threshold. We
also determined EBV EA-IgA by IEA method as a follow-up
conﬁrmatory test to verify the correctness of the rOD value we
selected. As a follow-up test for EBV-VCA IgA-positive samples, a
cut-off level of 1.60 exhibited the highest speciﬁcity (Table 3).
However, the EA-IgA ELISA was much less speciﬁc than the IEA. The
overall results indicated that the best cut-off rOD value for the
VCA-IgA ELISA, enabling the discrimination of NPC patients from a
high-risk population in southern China, is 1.60. The sensitivity and
speciﬁcity were 93.0% and 92.4%, respectively. This is much better
than the performance reported by Liu et al.,22 who determined the
sensitivity and speciﬁcity of VCA-IgA ELISA to be 91.1% and 80.7%,
respectively, at a the cut-off rOD of above 1. This study is the ﬁrst to
establish the cut-off level for EBV VCA-IgA ELISA in a high NPC
incidence area. This is meaningful in NPC-endemic areas like
southern China, where serological screening for NPC is often
included as part of the routine annual medical checkup. However,
the cut-off value identiﬁed in this study is not recommended for
direct use in populations other than those of southern China, since
regional differences may exist. Clinical laboratories should
establish a proper cut-off value to ﬁt their patient population
and test system. Besides, in this study, detection combined with
EA-IgA greatly reduced the sensitivity, suggesting that VCA-IgAries in 258 NPC patients: (a) depth of invasion (T factor); (b) lymph node metastasis
sity; VCA, viral capsid antigen; NPC, nasopharyngeal carcinoma.).
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VCA-IgA is recommended for screening high-risk populations,
followed by conﬁrmation by means of other serological markers
and biopsy for diagnosis. In this way we can greatly improve the
detection sensitivity and reduce unnecessary manpower and costs.
The EBV VCA-IgA titer is a reliable biomarker in serological
screening10 for NPC and a sensitive predictor of remission and
relapse.7–9 We clariﬁed the relationship between titers and rOD
levels. We found an excellent correlation and a high degree of
concordance between IgA titers and rOD levels, so that the VCA-IgA
ELISA method may also serve well as a diagnostic and prognostic
tool. We can estimate the patient’s titer according to the rOD
gradients provided by this study. This method combines the
advantages of ELISA and IEA. It is more easily standardized but less
labor-intensive when a large number of samples need to be
screened and quantitatively assessed for prognosis.
EBV DNA analysis by real-time PCR (RT-PCR) is now popular for
the screening and diagnosis of NPC. In this study, we also studied
the relationship between EBV DNA load from RT-PCR and rOD
values from EBV VCA-IgA ELISA. The EBV DNA loads for diagnosed
NPC patients in this study were quantiﬁed by RT-PCR, which
generated a positive rate of 66.3% (data not shown). This result is
similar to the sensitivity of EBV DNA (78%) reported in a systematic
review in Asia.23 According to our data, the sensitivity of RT-PCR for
EBV DNA is signiﬁcantly lower than VCA-IgA ELISA (Chi-square =
8.2, p = 0.004). And no correlation between EBV DNA load and rOD
values was found in this study (data not shown). Differences in
philosophy between the two methods may be the cause of the
variation in their results. Although EBV DNA load responds rapidly
to the treatment of NPC, the EBV DNA test has disadvantages that
prevent it from being a conventional tool for NPC screening. The
EBV DNA test requires more complicated procedures and advanced
equipment, as well as being more expensive. In contrast, testing
antibodies using an ELISA is cheap and labor-saving, and therefore
it is more convenient for NPC screening than the EBV DNA test.
Analyses of rOD levels for the different NPC stages showed that
the quantitative VCA-IgA ELISA for EBV may be useful for predicting
disease progression and the prognosis of patients with NPC, since a
rising trend of rOD was observed with the development of NPC
stages in this study. However, more evidence should be collected
through continuous studies before conclusions can be drawn. A
relationship was found between the rOD level and N factor (degree
of spread to the regional lymph nodes) of NPC, but no such
relationship was found for the T (size or direct extent of the primary
tumor) or M (presence of distant metastasis) factors. In particular, a
lower rOD was characterized in patients with tumor cells absent
from the regional lymph nodes in this study. Thus a high rOD level
for VCA-IgA might be a risk factor for tumor spread to the regional
lymph nodes in NPC patients. This result indicates that EBV infection
may be involved in the spread of tumor cells to the lymph nodes.
In summary, we established a semi-quantitative ELISA method
for serological screening of EBV VCA-IgA antibodies in NPC patients,
and through comparison with a normal healthy population and
patients with other tumors, a reﬁned cut-off value was obtained. We
also established the inter-relationship between the two methods of
ELISA and IEA. The increased throughput, reduced turnaround time,
and more standardized protocol make this ELISA assay an attractive
option for NPC screening and prognostic evaluation.
Our study had several limitations. The screening population will
be followed up until the end of 2013; undiagnosed NPCs in this study
may progress to NPC at a future date. The healthy control population
was selected randomly at a ﬁxed point in time. A random male/
female ratio of 0.5 was obtained (Table 2), whereas previous studies
have reported a male/female ratio of >2.0 for NPC. Although the
current literature indicates that males are at twice the risk, no
research so far has shown that males and females differ in serumconcentrations of VCA. For prognostic evaluation it is more suitable
to use the rOD value directly instead of comparing it with the titer.
However, due to the longer survival of NPC patients, long-term
monitoring should be performed as a credible follow-up study.
Ethics statement: This study was approved by the Institutional
Review Board (IRB) of Sun Yat-sen University Cancer Center.
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